Clinical Trial Update: A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Ampion in patients with prolonged respiratory symptoms due to COVID-19 (long COVID) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid

Drugs mentioned

• Ampion

Snippet

Sponsor: Ampio Pharmaceuticals. Inc. | Conditions: Covid19 | Phase 1 | Status: COMPLETED | Results posted: 2023-09-21